Fate Therapeutics, Inc.FATENASDAQ
LOADING
|||
R&D Expense Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-21.78%
↓ 173% below average
Average (9y)
29.91%
Historical baseline
Range
High:71.56%
Low:-46.14%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| 2024 | -21.78% |
| 2023 | -46.14% |
| 2022 | 48.69% |
| 2021 | 71.56% |
| 2020 | 43.13% |
| 2019 | 56.67% |
| 2018 | 63.06% |
| 2017 | 29.89% |
| 2016 | 33.19% |
| 2015 | 20.85% |